“Platform Technology”
01E.coli – based VLP Manufacturing Platform as an innovative solution against unmet and emerging viral infection
※ VLP : structurally resembling infectious virions, but non-infectious due to the lack the viral genome required for replication
02RIPT (RNA-Interaction mediated Protein manufacturing Technology)
High-yield & Fast VLP Manufacturing Platform Technology
03Strengths of E.coli-based VLP Vaccine
Conventional Viral Vaccine Manufacturing Process
Competitiveness of InThera VLP Vaccine
-
01. Virus Propagation
E.coli culture, instead of
mammalian cell culture

Increased facility efficiency and VLP manufacturing speed
-
04. Purification
High-level expression of
capsid protein
Purification through simple &
convenient process

Improved unwanted effect due to high purity
-
05. Inactivation
No denaturation of antigen
due to the lack of
chemical inactivation process

Improved immunogenicity